Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00075491 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme | terminated | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 |
| Jan 16, 2013 |
| clinicaltrials |
| NCT00430079 | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma | terminated | N/A | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | terminated | Phase 1 / Phase 2 | 28 | Bristol-Myers SquibbINDUSTRY | 4 | Aug 31, 2012 | clinicaltrials |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy | terminated | Phase 1 | 1 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Aug 29, 2012 | clinicaltrials |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2012 | clinicaltrials |
| NCT01105988 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | terminated | Early Phase 1 | 2 | Massachusetts General HospitalOTHER | 1 | Jan 6, 2012 | clinicaltrials |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00515086 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | terminated | Phase 2 | 30 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 231 | NovartisINDUSTRY | 1 | May 16, 2011 | clinicaltrials |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy(Glass-Art) | terminated | Phase 3 | 9 | Bradmer Pharmaceuticals Inc.INDUSTRY | 0 | Feb 10, 2011 | clinicaltrials |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | terminated | Phase 2 | 40 | Thallion PharmaceuticalsINDUSTRY | 2 | Dec 30, 2009 | clinicaltrials |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 3 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | terminated | Phase 2 | 40 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 22, 2009 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jan 24, 2013source: clinicaltrials